Chemours
CC · Diversified Chemicals
$12.81
1.7%Olin
OLN · Diversified Chemicals
$15.66
0.8%The short version
- Olin is the larger business, with $6.8B of revenue in fiscal 2025 against $5.8B for Chemours.
- Olin grew revenue faster (3.7%, against 0.5%).
- Olin turned more of its sales into free cash flow (3.7% FCF margin, against 0.9% FCF margin).
| Latest fiscal year | CC · FY25 | OLN · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.9B | $1.8B |
| Revenue | $5.8B | $6.8B |
| Free cash flow | $51.0M | $248M |
| Net income | −$386M | −$101M |
| Growth | ||
| Revenue growth | 0.5% | 3.7% |
| 5-year growth | 3.2% | 3.3% |
| Share count change | 0.0% | −4.1% |
| Profitability | ||
| Gross margin | 15.5% | 7.4% |
| Operating margin | — | 0.1% |
| Net margin | −6.7% | −1.5% |
| FCF margin | 0.9% | 3.7% |
| Return on capital | −0.2% | 0.1% |
| Return on equity | −94.0% | −5.2% |
| Balance sheet | ||
| Net debt | $3.5B | $2.7B |
| Net debt / EBITDA | 10.6x | 5.1x |
| Dividends and buybacks | $78.0M | $142M |
| Valuation & quality | ||
| P/E | — | — |
| Piotroski F-score | 4 | 4 |
FY16
CC $5.4B
OLN $5.6B
FY17
CC $6.2B
OLN $6.3B
FY18
CC $6.6B
OLN $6.9B
FY19
CC $5.5B
OLN $6.1B
FY20
CC $5.0B
OLN $5.8B
FY21
CC $6.3B
OLN $8.9B
FY22
CC $6.8B
OLN $9.4B
FY23
CC $6.1B
OLN $6.8B
FY24
CC $5.8B
OLN $6.5B
FY25
CC $5.8B
OLN $6.8B
CC
OLN
FY16
CC —
OLN 1.9%
FY17
CC —
OLN 4.7%
FY18
CC —
OLN 9.8%
FY19
CC —
OLN 2.9%
FY20
CC —
OLN −13.0%
FY21
CC —
OLN 20.8%
FY22
CC —
OLN 19.0%
FY23
CC —
OLN 10.4%
FY24
CC —
OLN 4.5%
FY25
CC —
OLN 0.1%
CC
OLN
FY16
CC $256M
OLN $325M
FY17
CC $229M
OLN $355M
FY18
CC $642M
OLN $523M
FY19
CC $169M
OLN $232M
FY20
CC $540M
OLN $134M
FY21
CC $537M
OLN $1.5B
FY22
CC $448M
OLN $1.7B
FY23
CC $186M
OLN $738M
FY24
CC −$993M
OLN $308M
FY25
CC $51.0M
OLN $248M
CC
OLN
FY16
CC 5.0%
OLN 1.5%
FY17
CC 29.5%
OLN 5.0%
FY18
CC 31.9%
OLN 8.4%
FY19
CC 1.7%
OLN 2.5%
FY20
CC 10.1%
OLN −11.1%
FY21
CC 21.6%
OLN 30.0%
FY22
CC 19.9%
OLN 27.7%
FY23
CC −2.4%
OLN 11.8%
FY24
CC 6.3%
OLN 4.6%
FY25
CC −0.2%
OLN 0.1%
CC
OLN
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.